NCT06403761 - Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

January 5, 2026

Study Completion Date

February 13, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants will receive once-weekly semaglutide subcutaneously.

DRUG

Cagrilintide

Participants will receive once-weekly cagrilintide subcutaneously.

DRUG

Placebo semaglutide

Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

DRUG

Placebo cagrilintide

Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

Trial Locations (1)

Profil Institut für Stoffwechselforschung GmbH, Neuss